High-performance liquid chromatographic methods for the determination of topoisomerase II inhibitors

被引:23
作者
Chen, CL
Thoen, KK
Uckun, FM [1 ]
机构
[1] Parker Hughes Inst, Parker Hughes Canc Ctr, Dept Oncol, St Paul, MN 55113 USA
[2] Parker Hughes Inst, Parker Hughes Canc Ctr, Dept Chem, St Paul, MN 55113 USA
[3] Parker Hughes Inst, Parker Hughes Canc Ctr, Dept Pharmaceut Sci, St Paul, MN 55113 USA
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2001年 / 764卷 / 1-2期
关键词
reviews; topoisomerase II inhibitors; enzymes;
D O I
10.1016/S0378-4347(01)00314-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Various methods for separating eleven different types of topoisornerase II (TOPO-2) inhibitors, including epipodophyllotoxins, anthracyclines, anthracenediones, anthrapyrazoles, anthracenebishydrazones, indole derivatives, amino-acridines, benzisoquinolinediones, isoflavones, bisdioxopiperazines and thiobarbituric. acids, are summarized. Proper sample preparation and storage is critical to the successful analysis of some TOPO-2 inhibitors due to difficulties associated with adsorption, instability and complex biological components. Solid-phase and liquid-liquid extractions are widely used to separate TOPO-2 inhibitors from biological samples, although simple deproteinization followed by direct analysis of the supernatant is preferable to extraction based on its speed and simplicity. High-performance liquid chromatography (HPLC) is the favored method for the bioanalysis of TOPO-2 inhibitors. UV or diode array detection is generally employed for early pharmacokinetic studies, while fluorescence or electrochemical detection is used more frequently for analytes with fluorescent or oxidative-reductive properties. For analyses requiring highly sensitive and/or specific detection, electrospray mass spectrometry (ESI-MS or ESI-MS-MS) provides a suitable alternative. A comprehensive compilation of the HPLC techniques currently used to separate TOPO-2 inhibitors will aid the future development of analytical methods for new TOPO-2 inhibitors. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:81 / 119
页数:39
相关论文
共 239 条
[1]  
Abigerges D, 1996, ANTI-CANCER DRUG, V7, P166
[2]  
AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
[3]   QUANTITATION OF DAUNORUBICIN AND ITS METABOLITES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].
AKPOFURE, C ;
RILEY, CA ;
SINKULE, JA ;
EVANS, WE .
JOURNAL OF CHROMATOGRAPHY, 1982, 232 (02) :377-383
[4]   High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues [J].
Alvarez-Cedrón, L ;
Sayalero, ML ;
Lanao, JM .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1999, 721 (02) :271-278
[5]   A SENSITIVE AND SIMPLE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF DOXORUBICIN AND ITS METABOLITES IN PLASMA [J].
ANDERSEN, A ;
WARREN, DJ ;
SLORDAL, L .
THERAPEUTIC DRUG MONITORING, 1993, 15 (05) :455-461
[6]  
ANDO S, 1986, CANCER TREAT REP, V70, P835
[7]   Catalytic inhibitors of DNA topoisomerase II [J].
Andoh, T ;
Ishida, R .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :155-171
[8]   Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors [J].
Aplan, PD ;
Chervinsky, DS ;
Stanulla, M ;
Burhans, WC .
BLOOD, 1996, 87 (07) :2649-2658
[9]   Mutagenic properties of topoisomerase-targeted drugs [J].
Baguley, BC ;
Ferguson, LR .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :213-222
[10]   Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy [J].
Barker, IK ;
Crawford, SM ;
Fell, AF .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 681 (02) :323-329